RZLT vs. RLMD, OPTN, CLRB, PMVP, COYA, CTXR, ALLK, RNAC, IMUX, and ABEO
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Relmada Therapeutics (RLMD), OptiNose (OPTN), Cellectar Biosciences (CLRB), PMV Pharmaceuticals (PMVP), Coya Therapeutics (COYA), Citius Pharmaceuticals (CTXR), Allakos (ALLK), Cartesian Therapeutics (RNAC), Immunic (IMUX), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
Relmada Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
In the previous week, Relmada Therapeutics had 5 more articles in the media than Rezolute. MarketBeat recorded 9 mentions for Relmada Therapeutics and 4 mentions for Rezolute. Rezolute's average media sentiment score of 0.67 beat Relmada Therapeutics' score of 0.50 indicating that Relmada Therapeutics is being referred to more favorably in the media.
45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by company insiders. Comparatively, 20.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Relmada Therapeutics' return on equity of -51.81% beat Rezolute's return on equity.
Rezolute received 38 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave Rezolute an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Relmada Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 608.22%. Rezolute has a consensus price target of $8.80, indicating a potential upside of 194.31%. Given Rezolute's higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Rezolute.
Rezolute is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Rezolute beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
